CNBC.com’s Pippa Stevens brings you the top business news headlines of the day. In today’s program, Meg Tirrell explains why the FDA and CDC called for stopping the administration of Johnson & Johnson vaccines after six women developed a rare blood clot disorder. In addition, Kate Rogers explores why restaurants have trouble hiring workers when diners return.
The FDA advises states to pause the use of the J&J Covid vaccine after a rare blood clotting problem affects 6 women and dies 1
The Food and Drug Administration on Tuesday called on states to temporarily stop the use of Johnson & Johnson’s Covid-19 vaccine “with great caution” after six U.S. women developed a rare blood clotting disorder that leaving one woman dead and another in critical condition.
“At this time, these adverse events appear to be extremely rare,” the FDA said in a joint statement with the Centers for Disease Control and Prevention. “The safety of the COVID-19 vaccine is a top priority for the federal government and we take all reports of health problems after vaccination against COVID-19 very seriously.”
All six cases occurred in women 18 to 48 years of age, with symptoms that developed six to 13 days after receiving the shot. Doctors usually treat this type of blood clot with heparin, but health regulators noted that in this case they could be dangerous and recommended a different treatment.
States rush to replace J&J vaccine appointments after FDA recommends a break
More than two dozen states on Tuesday took steps to stop inoculations with Johnson & Johnson’s coronavirus vaccine shortly after the Food and Drug Administration recommended stopping its use after reporting that some women developed a rare blood clotting disorder.
States, such as the FDA and the Centers for Disease Control and Prevention, stressed that they acted with great caution, as more than 6.8 million doses of J&J vaccine have been injected and so far only six of the cases blood clotting has been reported.
J&J said in a statement that “no clear causal relationship” has been identified between the rare type of blood clots and the vaccine, adding that it is working closely with regulators to evaluate the data.
Bitcoin reaches an all-time high above $ 63,000 before Coinbase debuts
Bitcoin hit a record high of more than $ 63,000 on Tuesday as investors expected the long-awaited stock market debut of cryptocurrency exchange Coinbase.
According to Coin Metrics data, the price of bitcoin rose to $ 63,236, before falling slightly to $ 62,877. It increased by about 5% in the last 24 hours. Ether, the second most valuable digital currency after Bitcoin, also set a new record, rising to $ 2,230.
Coinbase will go public on Wednesday through a direct listing that could value the company up to $ 100 billion, more than major mall operators like Intercontinental Exchange, which owns the New York Stock Exchange. Cryptographic investors celebrate the company’s stock market debut as a major milestone for the industry after years of skepticism on the part of Wall Street and regulators.